Different cardiovascular effects of progestins according to structure and activity

Climacteric

Volumn 12, Issue SUPPL. 1, 2009, Pages 96-101

  Nath, A ^a   Sitruk Ware, R ^a,b  

^a POPULATION COUNCIL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

ATHEROSCLEROSIS; HEMOSTASIS; PROGESTERONE; PROGESTINS; VASOMOTION

Indexed keywords

DESOGESTREL; DIENOGEST; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DYDROGESTERONE PLUS ESTRADIOL; ELCOMETRINE; ESTRADIOL; ESTRANE DERIVATIVE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; GLUCOCORTICOID; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MINERALOCORTICOID ANTAGONIST; NOMEGESTROL ACETATE; NORETHISTERONE; NORGESTIMATE; NORGESTREL; PLACEBO; PREGNANE DERIVATIVE; PROGESTERONE; TESTOSTERONE; TRIMEGESTONE; PROGESTERONE DERIVATIVE;

ANGINA PECTORIS; ARTICLE; ATHEROMA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL (TOPIC); DISEASE MARKER; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG STRUCTURE; ENDOTHELIUM CELL; HEART INFARCTION; HEART PROTECTION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; ANIMAL MODEL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; ESTROGEN THERAPY; FEMALE; MENOPAUSE; REVIEW; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MODELS, ANIMAL; PROGESTERONE CONGENERS; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 73949116539     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130902905757     Document Type: Article

References (19)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
2. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000;65:651-8
3. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77 (Pubitemid 46556472)
4. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-10
5. Zerr-Fouineau M, Jourdain M, Boesch E, Hecker M, Bronner C, Schini-Kerth B. Certain progestins prevent the enhancing effect of 17β-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol 2008, Dec. 18 [Epub ahead of print]
6. Simoncini T, Fu XD, Caruso A, et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 2007;22:2325-34 (Pubitemid 47241881)
7. Pedersen SH, Nielsen LB, Mortensen A, Nilas L, Ottesen B. Progestins oppose the effects of estradiol on the endothelin-1 receptor type B in coronary arteries from ovariectomized hyperlipidemic rabbits. Menopause 2008;15:503-10 (Pubitemid 351656756)
8. Williams JK, Cline JM, Honoré EK, Delansome R, Paris J. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in non human primates. Am J Obstet Gynecol 1998;179:1288-94 (Pubitemid 28533789)
9. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78 (Pubitemid 43231449)
10. Postmenopausal Estrogen/Progestin Intervention trial Writing Group. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208
11. Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995;64:957-62
12. Al-Azzawi F, Thompson J, Stevenson J. Which progestogen is more likely to increase the risk of fatal myocardial infarction; a combination of epidemiological and trial evidence. Maturitas 2006;54:154-63
13. Sitruk-Ware RL, Menard J, Rad M, et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception 2007;75:430-7 (Pubitemid 46764302)
14. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-84 (Pubitemid 41377417)
15. Knuuti J, Kalliokoski R, Janatuinen T, Kalliokoski KK, Koskenvuo J, Lundt S. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol 2007;99:1648-52 (Pubitemid 46874309)
16. Norris LA, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/dydrogesterone and estradiol (2 mg)/trimegestone. Thromb Haemost 2008;100:253-60
17. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006;53:252-9 (Pubitemid 43163060)
18. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001;104:2826-31 (Pubitemid 33126658)
19. Arnal JF, Gourdy P, Simoncini T. Interference of progestins with endothelial actions of estrogens. A matter of glucocorticoid action or deprivation? Arterioscler Thromb Vasc Biol 2009 Jan 29 [Epub ahead of print]